CLINICAL TRIALS PROFILE FOR CHOLESTYRAMINE
✉ Email this page to a colleague
All Clinical Trials for cholestyramine
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00000461 ↗ | Harvard Atherosclerosis Reversibility Project (HARP) | Completed | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 | 1986-12-01 | To determine by sequential coronary arteriography whether a lipid-lowering diet with and without lipid-lowering drugs could reverse coronary artery disease in normocholesterolemic patients. Also, to test whether fish oil supplements could improve human coronary atherosclerosis. Finally, to determine the effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. At least three clinical trials were conducted. |
| NCT00000463 ↗ | Post Coronary Artery Bypass Graft (CABG) Study | Completed | National Heart, Lung, and Blood Institute (NHLBI) | Phase 3 | 1987-04-01 | To determine the relative effectiveness of moderate versus more aggressive lipid lowering, and of low dose anticoagulation versus placebo, in delaying saphenous vein coronary bypass graft atherosclerosis and preventing occlusion of saphenous grafts of patients with saphenous vein coronary bypass grafts placed 1 to 11 years previously. |
| NCT00000488 ↗ | Lipid Research Clinics Coronary Primary Prevention Trial (CPPT) | Completed | National Heart, Lung, and Blood Institute (NHLBI) | Phase 3 | 1973-06-01 | To determine whether reduction of cholesterol by drug therapy significantly lowered the atherosclerotic coronary heart disease rate in a group of hypercholesterolemic but otherwise healthy men. Total dollars spent on the CPPT from June 1973 were $142,250,000. We do not have a year-by-year breakdown. |
| NCT00000594 ↗ | NHLBI Type II Coronary Intervention Study | Completed | National Heart, Lung, and Blood Institute (NHLBI) | Phase 3 | 1971-11-01 | To determine whether lowering of cholesterol with cholestyramine in a population with Type II hyperlipidemia led to a decreased rate of progression (a regression of coronary artery disease) as demonstrated by death, myocardial infarction, or progression of disease on angiography. |
| NCT00004266 ↗ | Drugs for High Blood Pressure and High Cholesterol in American Indians With Type 2 Diabetes | Completed | Hennepin County Medical Center, Minneapolis | Phase 3 | 1993-08-01 | OBJECTIVES: I. Establish a long-term working relationship between clinical investigators and the Minnesota American Indian community. II. Compare the effectiveness of lisinopril (an angiotensin-converting enzyme inhibitor) and nifedipine (a calcium channel blocker) in preventing nephropathy and vascular disease in Minnesota American Indians with non-insulin-dependent diabetes mellitus and microalbuminuria. III. Compare the effectiveness of simvastatin (a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor) with lipid-lowering strategies recommended by the National Cholesterol Education Program in preventing nephropathy and vascular diseases in these patients. |
| NCT00004266 ↗ | Drugs for High Blood Pressure and High Cholesterol in American Indians With Type 2 Diabetes | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 3 | 1993-08-01 | OBJECTIVES: I. Establish a long-term working relationship between clinical investigators and the Minnesota American Indian community. II. Compare the effectiveness of lisinopril (an angiotensin-converting enzyme inhibitor) and nifedipine (a calcium channel blocker) in preventing nephropathy and vascular disease in Minnesota American Indians with non-insulin-dependent diabetes mellitus and microalbuminuria. III. Compare the effectiveness of simvastatin (a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor) with lipid-lowering strategies recommended by the National Cholesterol Education Program in preventing nephropathy and vascular diseases in these patients. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for cholestyramine
Condition Name
Clinical Trial Locations for cholestyramine
Trials by Country
Clinical Trial Progress for cholestyramine
Clinical Trial Phase
Clinical Trial Sponsors for cholestyramine
Sponsor Name
